GlassScriptPhysician profile
Cristi Lynn Bundukamara
NPI 1730312497
$229,737.44
in general payments reported to CMS, 2019-2025
28 companies · $86K in 2025
The $86K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,345 · 2022: $7,263 · 2023: $63K · 2024: $73K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $137K · Consulting Fee: $42K · Travel and Lodging: $25K · Food and Beverage: $11K · Honoraria: $6,013 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137,457.50 |
| Consulting Fee | $42,165.00 |
| Travel and Lodging | $24,531.52 |
| Food and Beverage | $10,856.30 |
| Honoraria | $6,013.00 |
| Education | $106.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86,037.13 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $47,202.57 | 2021-2025 | Ingrezza |
| Abbvie INC. | $33,377.55 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $28,344.92 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $15,476.66 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $15,270.67 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $951.67 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $618.64 | 2021-2025 | Austedo, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $582.50 | 2021-2025 | Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $348.99 | 2021-2022 | |
| Lundbeck LLC | $279.44 | 2021-2025 | Rexulti, Brintellix |
| Vanda Pharmaceuticals INC. | $239.07 | 2021-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $145.43 | 2024-2025 | Loreev Xr |
| Indivior INC. | $120.50 | 2021-2024 | Perseris, Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $119.22 | 2021-2024 | Trintellix |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $91.41 | 2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $84.29 | 2021-2024 | Qelbree, Qelbree |
| Janssen Scientific Affairs, LLC | $69.38 | 2024-2025 | Invega Sustenna |
| Tempus Ai, INC | $66.77 | 2024 | |
| Bausch Health US, LLC | $58.43 | 2021 | |
| Ironshore Pharmaceuticals INC. | $50.12 | 2022-2023 | Jornay Pm |
| Eisai INC. | $49.61 | 2021-2022 | |
| Uswm, LLC | $37.68 | 2021 | |
| Corium, LLC | $37.13 | 2022 | |
| Merck Sharp & Dohme LLC | $22.35 | 2022 | |
| Livanova USA, INC. | $20.98 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Avanir Pharmaceuticals, INC. | $19.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.33 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristi Bundukamara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.